rel
assort
virus
caus
human
upper
respiratori
tract
infect
group
virus
caus
lower
respiratori
tract
infect
smaller
includ
influenza
parainfluenza
respiratori
syncyti
viru
cytomegaloviru
hantaviru
infect
mostli
limit
tracheobronch
healthi
individu
caus
sever
viral
pneumonia
immunocompromis
patient
influenza
one
bestknown
caus
pneumonia
intens
care
unit
icu
present
frequent
relat
bacteri
superinfect
staphylococcu
rariti
viral
pneumonia
attribut
type
cell
virus
infect
term
tropism
thu
common
influenza
strain
like
target
cell
trachea
bronchi
influenza
pneumonia
particularli
link
avian
strain
like
skip
upper
respiratori
epithelium
infect
alveolar
epitheli
cell
lower
respiratori
betacoronaviru
famili
includ
origin
sever
acut
respiratori
syndrom
sar
viru
well
middl
east
respiratori
syndromerel
coronaviru
mer
endem
human
pathogen
common
caus
cold
includ
betacoronavirus
around
yr
outbreak
lethal
strain
sarscov
middl
east
respiratori
syndromerel
coronaviru
ad
sarscov
middl
east
respiratori
syndromerel
coronaviru
like
origin
bat
sarscov
use
civet
intermediari
host
middl
east
respiratori
syndromerel
coronaviru
pass
though
camel
pangolin
also
known
scali
anteat
implic
passag
human
basi
sequenc
similar
pangolin
variabl
clinic
manifest
caus
distinct
coronaviru
strain
attribut
structur
differ
viru
protein
affect
tropism
replic
corona
descript
refer
crownlik
halo
viral
spike
protein
observ
electron
microscopi
fig
variat
sprotein
determin
protein
coronavirion
use
enter
cell
earli
investig
suggest
use
tissu
angiotensin
convert
receptor
trait
share
sar
middl
east
respiratori
syndromerel
coronaviru
common
endem
human
coronavirus
angiotensin
convert
express
lower
respiratori
tract
bronchi
well
enterocyt
small
thu
angiotensin
convert
depend
may
explain
clinic
present
lower
respiratori
tract
infect
enter
angiotensin
convert
express
vascular
endothelium
cardiac
myocyt
also
implic
acut
cardiac
injuri
result
anim
model
angiotensin
convert
enzym
inhibitor
angiotensinreceptor
blocker
increas
angiotensin
convert
express
activ
respect
lead
specul
medic
could
possibl
potenti
major
cardiolog
societi
recommend
chang
renin
angiotensin
aldosteron
system
antagonist
treatment
base
risk
site
express
angiotensin
convert
tongu
part
genitourinari
tract
clinic
signific
find
bind
sprotein
angiotensin
convert
like
contribut
directli
pathogenesi
result
downregul
angiotensin
convert
increas
product
angiotensin
ii
result
increas
pulmonari
vascular
angiotensin
convert
appear
univers
express
human
may
genet
variat
regul
angiotensin
convert
express
could
lead
differenti
suscept
across
popul
viral
bind
angiotensin
convert
viru
may
endocytos
directli
fuse
cell
membran
fig
positivesens
viral
rna
transcript
translat
host
cell
yield
two
polypeptid
polypeptid
subsequ
divid
viral
proteas
yield
viral
replic
machineri
coronavirus
employ
multipl
mechan
shield
viral
rna
host
detect
subsequ
induct
antivir
interferon
respons
includ
direct
antagon
interferon
signal
protein
replic
viral
rna
doubl
membran
nonetheless
strongli
induc
cytokin
chemokin
includ
tumor
necrosi
macrophag
inflammatori
suggest
broad
type
type
helper
tcell
remain
uncertain
extent
direct
viral
cytotox
versu
host
cytokin
storm
immun
respons
contribut
morbid
initi
coronaviru
infect
immun
respons
appear
effect
control
viral
infect
suggest
vaccin
feasibl
import
caveat
anim
vaccin
model
antibodi
respons
wane
quickli
indic
immun
respons
might
also
one
mous
coronaviru
model
sar
natur
killer
cell
antibodi
interferon
respons
benefici
tcell
respons
paradox
worsen
accordingli
vaccin
need
demonstr
safeti
effect
widespread
adopt
incub
period
appear
day
initi
report
demonstr
rapid
persontoperson
viral
transmiss
number
infect
individu
doubl
everi
viral
evolut
pattern
infer
viral
gene
sequenc
variat
suggest
much
viral
transmiss
occur
unit
state
undiagnos
two
case
report
week
apart
could
potenti
repres
cluster
hundr
two
distinct
group
sequenc
identifi
ltype
repres
case
wuhan
ancestr
stype
found
case
outsid
wuhan
postul
stype
could
less
sever
thu
capabl
rapid
spread
less
neg
select
major
patient
infect
present
fever
first
symptom
common
symptom
onset
ill
includ
cough
fatigu
less
commonli
report
symptom
includ
palpit
headach
diarrhea
subset
patient
develop
dyspnea
day
hospit
commonli
report
hematolog
laboratori
abnorm
leukopenia
caus
leukopenia
well
understood
could
relat
bone
marrow
suppress
lymphocyt
sequestr
clinic
spectrum
case
rang
asymptomat
critic
major
patient
mild
symptom
good
prognosi
patient
develop
pneumonia
acut
respiratori
distress
syndrom
ard
cardiac
injuri
renal
injuri
multiorgan
failur
day
hospit
subset
patient
requir
admiss
icu
respiratori
support
noninvas
invas
ventil
potenti
extracorpor
membran
summari
symptom
complic
treatment
initi
wave
case
seri
public
present
tabl
concern
anesthesiologist
periop
set
patient
present
minim
respiratori
symptom
one
initi
case
seri
patient
abdomin
symptom
admit
surgic
servic
infect
least
healthcar
abdomin
symptom
may
reflect
angiotensin
convert
express
small
intestin
potenti
underappreci
sinc
patient
gastrointestin
symptom
may
test
inde
may
transmit
via
rout
via
contamin
pneumonia
abnorm
chest
comput
tomographi
imag
detect
almost
hospit
patient
characterist
radiograph
find
ground
glass
opac
typic
bilater
peripher
coexist
consolid
cordlik
progress
revers
halo
crazypav
radiolog
pattern
may
becom
appar
notabl
radiolog
featur
rare
lymphadenopathi
nodul
pleural
effus
cavit
would
potenti
suggest
diagnosi
revers
transcriptasepolymeras
chain
reaction
test
standard
assay
throat
swab
nasal
swab
sampl
commonli
use
revers
transcriptasepolymeras
chain
reaction
revers
transcriptasepolymeras
chain
reaction
use
test
confirm
diagnosi
limit
sampl
collect
kit
perform
total
posit
rate
revers
transcriptasepolymeras
chain
reaction
throat
swab
sampl
report
initi
serial
revers
transcriptasepolymeras
chain
reaction
test
inclus
lower
airway
sampl
improv
sensit
test
commerci
avail
molecular
test
endem
coronavirus
filmarray
respiratori
panel
biofir
diagnost
usa
detect
current
expect
ad
chest
comput
tomographi
may
higher
sensit
infect
sensit
high
one
base
challeng
revers
transcriptasepolymeras
chain
reaction
test
comput
tomographi
imag
propos
primari
tool
detect
hospit
patient
epidem
area
howev
within
first
day
symptom
onset
major
patient
may
normal
comput
tomographi
thu
earli
diseas
cours
may
diagnost
suffici
sensit
exclud
patholog
find
report
mani
patholog
find
similar
seen
coronavirusassoci
sever
acut
respiratori
syndrom
caus
sarscov
middl
east
respiratori
coronaviru
inflammatori
infiltr
hyalin
membran
format
find
inspiss
spheric
secret
fibromyxoid
exud
promin
infect
accumul
thick
secret
like
caus
decreas
alveolar
ga
exchang
predispos
respiratori
failur
suggest
potenti
role
airway
clearanc
bronchial
hygien
treatment
full
ramif
infect
yet
understood
earli
work
point
wide
varieti
psychiatr
complic
affect
patient
famili
provid
larger
commun
relat
anxieti
isol
frustrat
stigma
diseas
also
pose
increas
risk
specif
subpopul
transplant
candid
patient
highlight
publish
case
seri
wide
variat
clinic
present
rang
symptom
intract
ard
shock
determin
vari
outcom
remain
unknown
experi
virus
suggest
variat
dose
viral
inoculum
rout
inocul
underli
immun
statu
patient
lead
wide
variabl
host
higher
viral
load
random
sampl
identifi
individu
greater
symptom
burden
greater
mortal
adenovir
time
moder
viral
load
detect
nasal
swab
week
onset
symptom
asymptomat
attribut
risk
higher
viral
inocula
difficult
quantifi
realworld
set
higher
viral
load
critic
ill
patient
pose
least
theoret
risk
healthcar
major
risk
factor
mortal
among
earli
report
case
old
age
underli
respiratori
reason
age
associ
unknown
multipl
theori
extrapol
biolog
exampl
immunosenesc
could
contribut
increas
risk
among
age
individu
age
frequenc
naiv
b
cell
diminish
impli
less
capac
recogn
adapt
novel
antigen
time
age
immun
cell
less
prolif
function
capac
even
respond
known
antigen
agerel
chang
cellular
immun
manifest
decreas
vaccin
effect
wors
outcom
set
influenza
respiratori
syncyti
viru
herp
zoster
demonstr
mous
model
coronaviru
lung
age
airway
epithelium
restor
capac
also
diminish
telomer
dysfunct
one
biolog
mechan
age
primarili
manifest
pulmonari
fibrosi
also
restrict
leukocyt
prolifer
conceiv
poor
outcom
could
link
short
telomer
report
pulmonari
fibrosi
ard
also
possibl
younger
individu
may
differenti
suscept
interestingli
rat
lung
angiotensin
convert
express
decreas
children
also
could
benefit
immun
develop
coronaviru
infect
inde
modest
crossreact
observ
endem
coronavirus
potenti
protect
crossreact
immun
would
limit
age
immunosenesc
transmiss
result
milder
gastroenter
present
also
conceiv
children
could
subsequ
protect
respiratori
syndrom
current
specul
caus
variat
present
mechan
like
hold
import
clue
inform
manag
therapeut
patient
appear
rel
mild
diseas
cours
subset
develop
hypoxem
respiratori
failur
imag
pattern
consist
diffus
viral
pneumon
organ
pneumonia
diffus
alveolar
true
incid
sever
pulmonari
diseas
associ
yet
clear
sever
studi
hubei
provinc
report
icu
admiss
rate
among
hospit
patient
confirm
ard
diagnosi
patient
admit
icu
tabl
among
patient
develop
dyspnea
hypoxemia
median
time
onset
symptom
develop
dyspnea
appear
day
ard
develop
smaller
subset
patient
manag
sever
hypoxemia
drawn
manag
ard
also
inform
experi
sarscov
middl
east
respiratori
coronaviru
outbreak
world
health
organ
publish
practic
guidelin
clinic
manag
sever
respiratori
sever
group
also
publish
practic
recommend
care
patient
treatment
patient
ard
made
complex
due
necessari
infect
control
intervent
use
isol
room
need
care
provid
wear
appropri
person
protect
equip
transmiss
patient
healthcar
worker
report
infect
control
primari
import
protect
healthcar
worker
prevent
spread
world
health
organ
guidelin
recommend
addit
routin
standard
precaut
provid
use
droplet
contact
precaut
care
patient
confirm
suspect
infect
addit
airborn
precaut
aerosolgener
procedur
intub
bronchoscopi
suction
cardiopulmonari
resuscit
addit
guidelin
frontlin
report
group
hubei
provinc
suggest
mani
provid
util
airborn
precaut
time
care
patient
addit
safeti
select
patient
respiratori
failur
present
hypoxemia
adequ
treat
low
flow
nasal
cannula
oxygen
convent
facemask
trial
either
noninvas
posit
pressur
ventil
heat
humidifi
high
flow
nasal
cannula
oxygen
may
reason
endotrach
intub
mechan
world
health
organ
manag
guidelin
among
other
suggest
trial
limit
durat
h
avoid
unrecogn
sever
respiratori
decompens
requir
emerg
intervent
use
high
flow
nasal
cannula
noninvas
posit
pressur
ventil
contraind
patient
hemodynam
instabl
multiorgan
failur
alter
mental
high
flow
nasal
cannula
provid
oxygen
patient
high
flow
rate
add
low
cm
posit
endexpiratori
pressur
peep
effect
reduc
work
breath
patient
acut
respiratori
high
flow
nasal
cannula
use
treat
ard
good
safeti
profil
given
recent
clinic
introduct
littl
data
outbreak
guid
use
associ
respiratori
one
studi
patient
ard
random
receiv
initi
high
flow
nasal
cannula
noninvas
posit
pressur
ventil
convent
oxygen
therapi
use
high
flow
nasal
cannula
significantli
reduc
intub
rate
overal
patient
random
high
flow
nasal
cannula
arm
lower
mortal
patient
moder
sever
ard
less
like
requir
convers
mechan
ventil
random
high
flow
nasal
cannula
arm
systemat
review
use
high
flow
nasal
cannula
ard
find
differ
mortal
intub
rate
compar
usual
care
found
high
flow
nasal
cannula
well
toler
use
novel
indic
ratio
oxygen
saturationfract
inspir
oxygen
respiratori
rate
may
help
predict
clinic
deterior
need
intub
high
flow
nasal
cannula
given
exist
literatur
base
use
high
flow
nasal
cannula
initi
strategi
treatment
respiratori
failur
appear
reason
patient
close
monitor
worsen
respiratori
distress
world
health
organ
guidelin
other
recommend
avoid
high
flow
nasal
cannula
use
patient
sever
worsen
hypercapnia
hemodynam
instabl
multiorgan
failur
alter
mental
although
guidelin
recommend
use
noninvas
posit
pressur
ventil
manag
acut
respiratori
failur
due
cardiogen
pulmonari
edema
patient
chronic
obstruct
pulmonari
diseas
copd
exacerb
lead
respiratori
acidosi
recommend
made
regard
use
noninvas
posit
pressur
ventil
use
noninvas
posit
pressur
ventil
patient
ard
evalu
sever
larg
trial
recent
studi
report
high
greater
rate
noninvas
posit
pressur
ventil
failur
lead
invas
mechan
ventil
patient
moder
sever
studi
noninvas
posit
pressur
ventil
failur
associ
increas
mortal
use
noninvas
posit
pressur
ventil
patient
sever
ard
less
mmhg
sever
author
suggest
increas
mortal
observ
noninvas
posit
pressur
ventil
use
patient
sever
ard
ultim
requir
invas
mechan
ventil
may
explain
noninvas
posit
pressur
ventil
delay
time
need
intub
lung
injuri
caus
uncontrol
high
tidal
volum
noninvas
posit
pressur
limit
data
suggest
noninvas
posit
pressur
ventil
deliv
via
helmet
patient
ard
failur
rate
mortal
may
lower
convent
noninvas
posit
pressur
ventil
facemask
use
helmet
mask
may
addit
benefici
infect
control
perspect
intervent
wide
experi
influenza
epidem
middl
east
respiratori
coronaviru
epidem
also
inform
recommend
use
noninvas
posit
pressur
ventil
larg
observ
studi
patient
report
greater
noninvas
posit
pressur
ventil
failur
rate
increas
mortal
patient
fail
initi
noninvas
posit
pressur
ventil
requir
invas
mechan
observ
studi
treatment
patient
middl
east
respiratori
coronaviru
report
greater
failur
rate
use
noninvas
posit
pressur
base
best
avail
data
use
noninvas
posit
pressur
ventil
initi
strategi
treatment
ard
like
reason
subset
patient
mild
ard
copd
exacerb
heart
failur
may
also
contribut
respiratori
distress
patient
close
monitor
improv
worsen
respiratori
substanti
concern
use
noninvas
posit
pressur
ventil
high
flow
nasal
cannula
patient
viral
respiratori
ill
result
increas
product
aerosol
viru
particl
creat
risk
healthcar
worker
contamin
clinic
environ
multipl
studi
sar
epidem
identifi
particip
tracheal
intub
risk
factor
viral
spread
healthcar
worker
noninvas
ventil
identifi
risk
factor
two
small
studi
consid
robust
enough
establish
risk
transmiss
experiment
studi
exhal
air
dispers
mannequin
isol
room
use
convent
low
flow
nasal
cannula
high
flow
nasal
cannula
continu
posit
airway
pressur
nasal
pillow
full
facemask
demonstr
greater
exhal
air
dispers
convent
low
flow
nasal
cannula
lmin
patient
face
compar
either
high
flow
nasal
cannula
continu
posit
airway
author
postul
lower
exhal
air
dispers
high
flow
nasal
cannula
continu
posit
airway
pressur
mask
could
relat
tighter
fit
face
modal
also
humidifi
air
gener
modal
could
result
exhal
larger
droplet
shorter
trajectori
due
use
full
noninvas
posit
pressur
ventil
facemask
might
also
prevent
spread
aerosol
droplet
patient
sneez
thu
risk
method
oxygen
deliveri
patient
respiratori
distress
result
spread
viruscontain
exhal
air
especi
mask
poorli
fit
leak
concern
use
noninvas
posit
pressur
ventil
high
flow
nasal
cannula
specif
lead
wors
environment
contamin
substanti
current
avail
evid
patient
receiv
supplement
oxygen
therapi
care
airborn
isol
room
whenev
possibl
staff
use
full
contact
droplet
airborn
isol
provid
awar
coronavirus
remain
infecti
inanim
surfac
day
surfac
equip
use
patient
care
disinfect
greater
ethanol
small
surfac
greater
sodium
hypochlorit
larger
regardless
choic
initi
oxygen
therapi
patient
respiratori
failur
patient
close
monitor
deterior
intub
promptli
avoid
need
emerg
experi
sar
epidem
suggest
intub
time
healthcar
worker
high
risk
viral
transmiss
infect
patient
odd
ratio
note
howev
sever
healthcar
provid
contract
sar
intub
patient
wear
standard
surgic
facemask
time
intub
strong
evid
link
intub
risk
transmiss
viru
healthcar
worker
proper
airborn
precaut
note
sever
post
hoc
report
sar
epidem
emerg
report
current
epidem
recommend
use
higher
level
person
protect
equip
power
airpurifi
respir
doubl
glove
coveral
foot
cover
hood
perform
aerosol
gener
procedur
intub
appear
evid
support
superior
measur
standard
droplet
contact
aerosol
even
suggest
use
increas
layer
barrier
precaut
without
strong
evid
support
applic
make
patient
care
challeng
could
increas
risk
contamin
lengthi
complex
person
protect
equip
remov
applic
full
barrier
precaut
report
take
least
min
ideal
perform
endotrach
intub
indic
world
health
organ
clinic
guidelin
suggest
perform
experienc
provid
use
airborn
guidelin
also
recommend
use
modal
nonrebreath
mask
bag
valv
mask
high
flow
nasal
cannula
noninvas
posit
pressur
ventil
preoxygen
oxygen
min
use
rapid
sequenc
induct
possibl
avoid
cough
need
posit
pressur
addit
guidelin
experienti
report
hubei
provinc
larg
echo
note
data
recent
metaanalysi
note
benefit
use
high
flow
nasal
cannula
periintub
preoxygen
compar
usual
oxygen
therapi
patient
hypoxem
respiratori
howev
high
flow
nasal
cannula
may
benefit
prevent
sever
hypoxemia
intub
prolong
apneic
time
patient
sever
see
tabl
addit
clinic
recommend
regard
airway
manag
intub
manag
respiratori
failur
ard
caus
us
european
union
recent
releas
unit
kingdom
ard
guidelin
strongli
recommend
use
low
tidal
volum
ventil
mlkg
predict
bodi
weight
useuropean
union
guidelin
less
mlkg
unit
kingdom
guidelin
maintain
plateau
pressur
less
cm
permiss
us
european
union
unit
kingdom
guidelin
also
strongli
recommend
use
prone
posit
greater
h
per
day
patient
sever
moderatesever
unit
kingdom
guidelin
ard
recommend
echo
world
health
organ
howev
prone
ventil
resourceintens
intervent
endotrach
tube
line
may
becom
displac
recommend
suffici
human
resourc
expertis
within
medic
center
intervent
perform
world
health
organ
guidelin
manag
echo
unit
kingdom
ard
guidelin
recommend
conserv
fluid
manag
strategi
patient
without
evid
tissu
useuropean
union
unit
kingdom
ard
guidelin
weakli
recommend
use
higher
peep
moder
sever
ard
unit
kingdom
guidelin
weakli
recommend
use
neuromuscular
blockad
continu
infus
earli
moder
sever
ard
recent
clinic
trial
challeng
recommend
thu
variou
compon
best
clinic
practic
ard
remain
unclear
larg
multicent
trial
patient
random
receiv
either
convent
low
peep
ventil
strategi
titrat
peep
strategi
result
high
peep
combin
lung
recruit
maneuv
found
increas
mortal
higher
peep
lung
recruit
maneuv
regard
use
neuromuscular
blockad
recent
multicent
random
trial
found
mortal
benefit
use
earli
moder
sever
ard
advers
cardiovascular
event
paralysi
arm
trial
mind
world
health
organ
guidelin
suggest
cautiou
use
higher
peep
moder
sever
ard
routin
use
neuromuscular
patient
refractori
hypoxemia
despit
lung
protect
ventil
best
practic
limit
data
guid
effect
use
extracorpor
membran
oxygen
unit
kingdom
ard
guidelin
weakli
recommend
consider
extracorpor
membran
oxygen
patient
sever
ard
refractori
hypoxemia
although
recommend
publish
result
random
control
trial
extracorpor
membran
oxygen
ard
stop
earli
due
lack
statist
signific
mortal
benefit
extracorpor
membran
oxygen
group
medic
manag
howev
reanalysi
data
trial
well
metaanalysi
incorpor
new
trial
data
suggest
extracorpor
membran
oxygen
may
provid
mortal
benefit
patient
sever
small
casecontrol
seri
middl
east
respiratori
coronaviru
outbreak
use
extracorpor
membran
oxygen
refractori
hypoxemia
associ
lower
inhospit
consid
data
may
reason
refer
patient
refractori
hypoxemia
despit
lung
protect
ventil
extracorpor
membran
oxygen
center
expertis
resourc
properli
manag
complex
patient
respiratori
failur
develop
superimpos
septic
shock
adher
standard
sepsi
treatment
protocol
addit
nonevidencebas
recommend
manag
respiratori
failur
promulg
varieti
guidelin
publish
sourc
larg
focus
minim
viral
spread
healthcar
worker
environ
recommend
includ
minim
ventil
disconnect
use
inlin
cathet
airway
use
high
effici
hydrophob
filter
patient
breath
avoid
use
nebul
medic
favor
meter
dose
inhal
bronchodil
collect
list
practic
recommend
guid
anesthet
critic
care
manag
patient
found
tabl
tabl
provid
list
organ
offer
updat
guidelin
resourc
provid
care
patient
face
rapidli
emerg
global
threat
sever
reason
optim
futur
control
describ
number
antivir
drug
shown
promis
vitro
even
partial
effect
antivir
could
allow
suffici
reduct
viral
load
immun
system
recov
respond
prevent
lethal
diseas
even
potenti
antivir
could
use
chemoprophylaxi
prevent
transmiss
recent
expos
individu
resist
antivir
develop
quickli
patient
hiv
studi
coronavirus
suggest
might
less
similarli
hiv
readili
evad
cellular
humor
immun
sharpli
limit
vaccin
sarscov
infect
appear
induc
broad
longlast
immun
less
evid
immun
thu
like
evolv
physician
varieti
therapeut
vaccin
option
minim
morbid
mortal
arriv
anesthesiologist
call
upon
provid
support
care
minim
risk
viral
transmiss
other
work
support
part
career
develop
award
us
depart
veteran
affair
clinic
scienc
research
develop
servic
washington
dc
content
repres
view
us
depart
veteran
affair
unit
state
govern
dr
greenland
report
follow
financi
relationship
relat
public
boehring
ingelheim
ridgefield
connecticut
therav
biopharma
south
san
francisco
california
genentech
south
san
francisco
california
atara
biotherapeut
south
san
francisco
california
biofir
diagnost
salt
lake
citi
utah
thermo
fisher
waltham
massachusett
dr
london
report
ongo
financi
relationship
springer
verlag
current
anesthesiolog
report
springer
natur
group
new
york
new
york
uptod
wolter
kluwer
philadelphia
pennsylvania
american
societi
anesthesiologist
schaumburg
illinoi
author
declar
compet
interest
